Screener
United Therapeutics UTHR Stock Issuance Proceeds
Stock Issuance Proceeds at other companies
Other financials
Where this comes from
Reported directly by United Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromStockOptionsExercised.
The source filing: United Therapeutics’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 6:31 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001082554-26-000027
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Repayment of line of credit | — | (500.0) |
| Excise tax paid on net share repurchase | — | (5.0) |
| Payments of debt issuance costs | (3.4) | (11.5) |
| Proceeds from the exercise of stock options | 194.6 | 34.7 |
| Proceeds from the issuance of stock under ESPP | 5.6 | 4.9 |
| RSUs withheld for taxes | (58.8) | (15.5) |
| Net cash used in financing activities | (1,362.0) | (292.4) |
| Net increase (decrease) in cash and cash equivalents | $246.1 | $(104.1) |
Item 1. Consolidated Financial Statements
FAQ
- What is United Therapeutics's stock issuance proceeds?
- United Therapeutics (UTHR) reported stock issuance proceeds of $126.3M in Q2 2026.
- How has United Therapeutics's stock issuance proceeds changed year-over-year?
- United Therapeutics's stock issuance proceeds increased by 597.8% year-over-year, from $18.1M to $126.3M.
- What is the long-term trend for United Therapeutics's stock issuance proceeds?
- Over 4 years (2021 to 2025), United Therapeutics's stock issuance proceeds has grown at a 36.6% compound annual growth rate (CAGR), from $50M to $173.9M.
- What does stock issuance proceeds mean?
- Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.
Ask your AI about United Therapeutics's stock issuance proceeds.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude